These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30075600)

  • 21. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
    Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
    Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
    Molina R; Escudero JM; Augé JM; Filella X; Foj L; Torné A; Lejarcegui J; Pahisa J
    Tumour Biol; 2011 Dec; 32(6):1087-95. PubMed ID: 21863264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?
    Kaijser J; Van Gorp T; Smet ME; Van Holsbeke C; Sayasneh A; Epstein E; Bourne T; Vergote I; Van Calster B; Timmerman D
    Ultrasound Obstet Gynecol; 2014 Jan; 43(1):89-97. PubMed ID: 23828371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraoperative laparoscopic sonography for improved preoperative sonographic pathologic characterization of adnexal masses.
    Yang WT; Yuen PM; Ho SS; Leung TN; Metreweli C
    J Ultrasound Med; 1998 Jan; 17(1):53-61. PubMed ID: 9440109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
    Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
    J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
    Czekierdowski A
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
    Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study.
    Choi HJ; Lee YY; Sohn I; Kim YM; Kim JW; Kang S; Kim BG
    Curr Probl Cancer; 2020 Apr; 44(2):100508. PubMed ID: 31708114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses.
    Gentry-Maharaj A; Burnell M; Dilley J; Ryan A; Karpinskyj C; Gunu R; Mallett S; Deeks J; Campbell S; Jacobs I; Sundar S; Menon U
    Am J Obstet Gynecol; 2020 Jan; 222(1):56.e1-56.e17. PubMed ID: 31351062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case-control study.
    Pitynski K; Sporek A; Lipinska I; Banas T; Ludwin A; Bałajewicz-Nowak M
    Taiwan J Obstet Gynecol; 2015 Dec; 54(6):766-72. PubMed ID: 26701000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass.
    Dora SK; Dandapat AB; Pande B; Hota JP
    J Ovarian Res; 2017 Aug; 10(1):55. PubMed ID: 28806987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison of laparoscopic vs. laparotomy treatment in ovarian teratomas].
    Briones-Landa CH; Ayala-Yáñez R; Leroy-López L; Anaya-Coeto H; Santarosa-Pérez MA; Reyes-Muñoz E
    Ginecol Obstet Mex; 2010 Oct; 78(10):527-32. PubMed ID: 21966769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The management of adnexal masses in premenopausal patients: a ten-year retrospective study at a single center.
    Ozcan HC; Balat O; Ugur MG; Kul S; Bozdag Z; Sucu S; Keklikcioglu I
    Eur J Gynaecol Oncol; 2017; 38(3):372-377. PubMed ID: 29693876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adding cancer antigen 125 screening to gray scale sonography for predicting specific diagnosis of benign adnexal masses in premenopausal women: is it worthwhile?
    Alcázar JL; Guerriero S; Mínguez JÁ; Ajossa S; Paoletti AM; Ruiz-Zambrana A; Jurado M
    J Ultrasound Med; 2011 Oct; 30(10):1381-6. PubMed ID: 21968488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal.
    Melo Â; Veríssimo R; Farinha M; Martins NN; Martins FN
    J Obstet Gynaecol; 2018 Nov; 38(8):1140-1145. PubMed ID: 29884096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women.
    Nikolova T; Zivadinovic R; Evtimovska N; Klisarovska V; Stanojevic M; Georgievska J; Nikolova N
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1870-1879. PubMed ID: 29027715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M; Kristjansdottir B; Sundfeldt K
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transvaginal ultrasound and computed tomography combined with clinical parameters and CA-125 determinations in the differential diagnosis of persistent ovarian cysts in premenopausal women.
    Guerriero S; Mallarini G; Ajossa S; Risalvato A; Satta R; Mais V; Angiolucci M; Melis GB
    Ultrasound Obstet Gynecol; 1997 May; 9(5):339-43. PubMed ID: 9201878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour markers and histopathologic features of ovarian endometriotic cysts.
    Selcuk S; Kucukbas M; Koc N; Cam C; Ozkaya E; Eser A; Karateke A
    J Obstet Gynaecol; 2021 Jul; 41(5):763-768. PubMed ID: 33054460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.